Durability of the BNT162b2 XBB.1.5-adapted vaccine against JN.1 hospitalisation in Europe, October 2023 to August 2024: A test-negative case-control study using the id.DRIVE platform” (pre-print).

HR Volkman, L de Munter, JL Nguyen, TMP Tran, M Mitratza, C Marques, L Choi, S Valluri, J Yang, A Antón, I Casas, E Conde-Sousa, L Drikite, B Grüner, G Icardi, G Luit ten Kate, C Martin, A Mira-Iglesias, A Orrico-Sánchez, S Otero-Romero, G Rohde, L Jodar, JM McLaughlin, K Bollaerts.

MedRxiv (2025) – preprint
https://doi.org/10.1101/2025.05.02.25326904